Category survey

Neurophysiological mechanisms underlying parkinsonian motor signs Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Rational derivation of DA neuron subtypes from iPS cells for improved modelling of Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Metabolomics and risk of Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

VALIDATION OF NEUROIMAGING BIOMARKERS FOR NIGROSTRAITAL NEURONS Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Investigating CD47-SIRPa as novel protective signals during CNS synaptic pruning Investments > €500k United States of America Huntington’s disease 2016    

Huntingtons disease repeat instability and pathogenesis Investments > €500k United States of America Huntington’s disease 2016    

GBA pathway markers for Lewy body dementias Investments > €500k United States of America Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Basal Ganglia Cortical Coupling and Connectivity Changes in PD and DBS Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Mobile Decision Support System for Nurse Management of Neuromodulation Therapy Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Intersection of alpha synuclein and tau contributions to neurotoxicity Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Mechanism of modulation of huntingtin exon 1 aggregation by profilin Investments > €500k United States of America Huntington’s disease 2016    

Epigenetic pathology and therapy in Huntingtons disease Investments > €500k United States of America Huntington’s disease 2016    

Neural Toxicity of Paraquat is Related to Iron Regulation in the Midbrain Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Chemical Fingerprinting Investments > €500k United States of America Huntington’s disease 2016    

Influence of neuromuscular pathology on parkinsonian communication deficits Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

More than a Movement Disorder: Applying Palliative Care to Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Synaptic Transmission, Plasticity and Integration in the Subthalamic Nucleus Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Cyclic EphA4 peptide antagonists for neuroprotection in ALS Investments > €500k United States of America Motor neurone diseases 2016    

Pathway targeted deep brain stimulation for Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Remote Electromagnetic Control of Neural Activity for Treatment of Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Human iPSC-based personalized cell therapy of PD Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Positive Allosteric Modulators as PET Imaging Ligans for mGluR4 Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

PATHOLOG-OMICS – ESSENTIAL TREMOR IN THE BROADER CONTEXT OF NEURODEGENERATION Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Validation of the HD-HRQOL (Huntington disease quality of life measure) Investments > €500k United States of America Huntington’s disease 2016    

Genomic and functional analysis of transcriptome changes in Huntingtons Disease Investments > €500k United States of America Huntington’s disease 2016    

Identifying Factors Regulating Medium Spiny Neuron Differentiation or Maintenance as Therapeutic Targets for Huntingtons Disease using Induced Pluripotent Stem Cells Investments > €500k United States of America Huntington’s disease 2016    

Predictive model of spread of Parkinsons pathology using network diffusion Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Cortico-basal ganglia connectivity in a non-human primate model of Huntingtons disease Investments > €500k United States of America Huntington’s disease 2016    

SPEECH MOVEMENT CLASSIFICATION FOR ASSESSING AND TREATING ALS Investments > €500k United States of America Motor neurone diseases 2016    

Integrating Quality Control: Studies of UBQLN2 in Age-Related Neurodegeneration Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Peripheral and Central Postural Disorders in the Elderly Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Individualized Cell Therapy for Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Validation of Novel Pathogenic Htt Post-Translational Modifications (PTMs) Investments > €500k United States of America Huntington’s disease 2016    

Quantitative mapping of substantia nigra iron in Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Diagnostic and prognostic biomarkers for Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Disease-Modifying Genes in Huntingtons Diseae Investments > €500k United States of America Huntington’s disease 2016    

Dementia with Lewy Bodies Consortium Investments > €500k United States of America Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Large Scale Biomarker Discovery and Validation for Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Tolerability of SRX246 in Huntingtons Disease Patients Investments > €500k United States of America Huntington’s disease 2016    

An iPSC based platform for functionally assessing genetic and environmental risk Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Targeting Lewy Body Specific Pathology Using Biomarkers Investments > €500k United States of America Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Neurochemical Actions of Psychotropic Drugs Investments > €500k United States of America Huntington’s disease 2016    

Multimodal MRI markers of nigrostriatal pathology in Parkinsons disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Exosome based therapeutics in Huntingtons disease Investments > €500k United States of America Huntington’s disease 2016    

Johns Hopkins Medicine Biomarker Discovery in Parkinsons Disease Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Lewy Body Dementia Biomarkers Investments > €500k United States of America Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model. Investments > €500k United States of America Motor neurone diseases 2016    

INVESTIGATIONS OF DEMENTIA IN PARKINSON DISEASE Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Environmental Epidemiology of Essential Tremor Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016